Stephen G Marcus
Cantex Pharmaceuticals
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephen G Marcus as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05986851 · Azeliragon in MGMT Unmethylated GlioblastomaCantex Pharmaceuticals · active not recruiting · Glioblastoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:06 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse.Clin Gastroenterol Hepatol · 201595 citationsRCR 4.1
- Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.J Interferon Res · 199395 citationsRCR 2.7
- Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.Blood Adv · 201852 citationsRCR 1.9
- Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.J Gastrointest Surg · 200232 citationsRCR 0.9
- Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.Br J Cancer · 200631 citationsRCR 0.9
- Phase II trial of recombinant beta interferon in advanced colorectal cancer.Cancer Treat Rep · 198729 citationsRCR 0.8
- Clinical application of IL6 in cancer therapy.Res Immunol · 199218 citationsRCR 0.5
- A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.J Neurooncol · 199017 citationsRCR 0.5
- Serial MR in gene therapy for recurrent glioblastoma: initial experience and work in progress.AJNR Am J Neuroradiol · 199713 citationsRCR 0.4
- 9 citationsRCR 0.2